Recent Advancements in Cancer Immunotherapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 152
Special Issue Editor
Interests: cancer stem cells; cancer recurrence; therapeutic resistance; tumor microenvironment; signaling pathways; targeted therapy; head and neck cancer; lung cancer; bladder cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapy employs targeted modulation of the immune system to enhance antitumor activity, representing a major shift from conventional cytotoxic therapies. Core immunologic processes—such as antigen presentation by dendritic cells, T‑cell activation, and immune surveillance—form the foundation of therapeutic efficacy. Established modalities, including immune checkpoint inhibitors and adoptive cell transfer, have significantly improved outcomes in malignancies like melanoma, non‑small‑cell lung cancer, and hematologic cancers. CAR‑T cell therapy has extensive use in B‑cell malignancies but remains constrained in solid tumors due to antigenic heterogeneity, restricted immune infiltration, and suppressive tumor microenvironmental factors. Emerging strategies integrate immunotherapy with radiotherapy or chemotherapy to enhance immune responsiveness. Additionally, tumor genomics, epigenetic regulation, and microbiome composition are increasingly recognized as determinants of therapeutic sensitivity and resistance. Despite ongoing challenges—such as immune‑related toxicity and manufacturing limitations—advances in biomarker‑guided approaches and engineered delivery systems are driving more precise and scalable immunotherapeutic solutions. We are pleased to invite you to submit your research work to this Special Issue on recent advancements in cancer immunotherapy.
This Special Issue aims to publish articles on the following themes:
- Mechanistic Foundations of Anticancer Immunity;
- Immune Evasion and Tumor‑Driven Resistance Mechanisms;
- Advances in Immune Checkpoint Inhibition;
- CAR‑T Cell Therapy: Progress, Limitations, and Innovations;
- Combinations of Immunotherapeutic Strategies;
- Nanotechnology‑Enabled Immunotherapy;
- Role of the Tumor Microenvironment in Immunotherapy Outcomes;
- Microbiome–Immunity Interactions in Cancer Treatment;
- Biomarker‑Driven Personalization of Immunotherapy;
- Toxicity Profiles and Safety Management in Cancer Immunotherapy.
Dr. Pritam Sadhukhan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint inhibitor
- PD-1 inhibitor
- PDL-1 inhibitor
- CTLA-4 inhibitor
- B7H3 inhibitors
- CAR-T cell therapy
- nanotechnology in immunotherapy
- tumor microenvironment remodeling
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
